1 year ago
RPG Life Sciences Reports Q1 Dip in PAT, Revenue Up
RPG Life Sciences, a company, made less profit in the last three months compared to last year, but they still made a lot of money.
They made more money from selling things, even though their profit was a little lower.
The company is doing well with medicines sold in their country.
They plan to sell more medicines in other countries and make new medicines.
They are also looking for ways to buy other companies to grow even faster.
RPG Life Sciences' Q1 profit after tax (PAT) dipped to ₹26.29 crore.
Revenue from operations increased by 2% to ₹168.92 crore.
The company's domestic formulations business showed market-beating growth.
RPG Life Sciences plans to accelerate its International Formulations and API segments.
The company is exploring inorganic growth opportunities in formulations and APIs.
- Who
- RPG Life Sciences, led by Managing Director Ashok Nair.
- What
- RPG Life Sciences reported financial results for Q1, with a dip in PAT but increased revenue.
- Where
- No specific location is mentioned, but the company is part of the RPG group.
- When
- The financial results are for the June 2025 quarter.
- Why
- The company is sustaining sales growth and aiming for further expansion.
Key facts
- PAT (Q1)
- ₹26.29 crore
- PAT (Q1 FY25)
- ₹26.76 crore
- Revenue from Operations
- ₹168.92 crore
- Revenue from Operations (Q1 FY25)
- ₹165.42 crore
- Managing Director
- Ashok Nair
